nf-kb

Scope note (updated 2026-05-07): Reactome R-HSA-9020702 was INCORRECT (confirmed = “Interleukin-1 signaling” per ContentService API) — corrected to null with sub-pathway candidates listed in frontmatter. KEGG hsa04064 confirmed correct via KEGG REST API. WikiPathways WP3539 not independently re-verified (API returned errors). Salminen 2008 claims are unverifiable (not_oa). Drosophila, NEMO-het, and C. elegans lifespan claims remain unsourced.

NF-κB signaling pathway

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a family of master transcription factors that coordinates the inflammatory gene expression program in virtually all nucleated mammalian cells. In normal physiology NF-κB activation is transient, self-limiting, and essential for immunity and tissue repair. In aging, NF-κB becomes persistently and aberrantly activated — a state that underpins inflammaging, drives the SASP from senescent cells, and promotes most age-related pathologies. Of the two hallmark-level connections, the NF-κB → SASP link is the better-mechanistically-understood: senescent cells lock NF-κB in the “on” state via an IL-1α autocrine loop, producing a chronic inflammatory secretome that propagates tissue dysfunction throughout aging.

Naming note: This page covers the NF-κB signaling pathway and is the canonical [[nf-kb]] wikilink target. Individual subunit proteins (RelA/p65, p50, p52, RelB, c-Rel) can be seeded as molecules/proteins/rela.md etc. when needed. Greek κ → “k” in filename per CLAUDE.md naming convention; aliases include the Greek-letter forms.

The NF-κB family — five subunits, two activation arms

NF-κB is not a single protein but a family of five transcription factor subunits that homo- and heterodimerize to form the active complexes ¹:

Subunit	Gene	Inhibitory domain?	Preferred dimer partner	Primary function
RelA (p65)	RELA	No (requires IκB)	p50	Canonical, pro-inflammatory
RelB	RELB	No (requires IκB)	p52	Non-canonical, lymphoid development
c-Rel	REL	No (requires IκB)	p50	Immune cell survival
p50 / NF-κB1	NFKB1	Precursor p105 processed to p50	RelA, c-Rel	DNA-binding only (no transactivation domain)
p52 / NF-κB2	NFKB2	Precursor p100 processed to p52	RelB	Non-canonical

All subunits share an N-terminal Rel Homology Domain (RHD) that mediates DNA binding, dimerization, and interaction with IκB inhibitory proteins ¹. Dimers lacking a transactivation domain (e.g., p50/p50 homodimers) can occupy κB sites and act as transcriptional repressors, providing a built-in negative regulatory layer.

Canonical activation pathway (IKK-dependent)

The canonical pathway — activated by TNF-α, IL-1β, pathogen-associated molecular patterns (PAMPs) via Toll-like receptors, and genotoxic stress — proceeds in four steps ^{1 2}:

1. Signal reception — TNF binds TNFR1 → recruits TRADD/TRAF2/RIP1 scaffold; IL-1β binds IL-1R → recruits myd88/IRAK4/TRAF6; TLR stimulation also signals through myd88. The K63-polyubiquitin scaffold built by traf6 recruits and activates tak1 (MAP3K7), which directly phosphorylates IKKβ to relay the signal into step 2.
2. IKK complex activation — all three routes converge on the IκB Kinase (IKK) complex: IKKα (IKK1), IKKβ (IKK2), and the regulatory scaffold NEMO (IKKγ). IKKβ is the primary catalytic subunit in canonical signaling, activated by tak1-mediated phosphorylation at the activation-loop serines. IKK phosphorylates IκBα at Ser32 and Ser36.
3. IκBα degradation — phosphorylated IκBα is polyubiquitinated by the SCF^βTrCP^ E3 ligase complex and degraded by the 26S proteasome. This liberates the p65/p50 dimer.
4. Nuclear translocation — free p65/p50 enters the nucleus, binds κB sites (consensus 5′-GGGRNWYYCC-3′; N=any base, R=purine, W=adenine or thymine, Y=pyrimidine ²), and recruits coactivators (CBP/p300, BRD4) to activate target genes.

Canonical signaling is rapid (~15 min), self-limiting (NF-κB drives its own repressor IκBα re-synthesis, creating a negative feedback loop), and returns to baseline within 1–2 hours under normal conditions ². Persistent activation in aging breaks this self-limiting behavior.

Non-canonical activation pathway (NIK-dependent)

The non-canonical pathway is activated by a restricted set of signals — BAFF, CD40L, lymphotoxin-β, and RANKL — and is central to secondary lymphoid organogenesis and adaptive immunity ¹:

1. NIK stabilization — basal NIK is constitutively degraded by the TRAF3/TRAF2/cIAP1/cIAP2 E3 ligase complex. BAFF/CD40L engagement triggers cIAP-mediated TRAF3 degradation → NIK accumulates.
2. p100 processing — accumulated NIK activates IKKα, which phosphorylates p100 (the NF-κB2 precursor) → SCF^βTrCP^-mediated ubiquitination → proteasomal processing releases p52 from the p100 inhibitory ankyrin repeats.
3. p52/RelB nuclear entry — the p52/RelB dimer enters the nucleus to activate a distinct, partially non-overlapping gene expression program.

The non-canonical pathway is slow (hours), does not involve IκBα degradation, and regulates distinct target genes (chemokines for B-cell homing, BAFF receptor expression, osteoclastogenesis). It is less directly implicated in inflammaging but relevant to age-related immune dysfunction.

NF-κB in aging — the inflammaging axis

Persistent activation in senescent cells — the SASP connection

The most mechanistically-detailed connection between NF-κB and aging is its role as the master transcriptional driver of the SASP (Senescence-Associated Secretory Phenotype). In senescent cells, unlike in normal cells responding to stress, NF-κB activation is not self-limiting ³:

• IL-1α autocrine loop — IL-1α, a SASP component and membrane-anchored precursor, signals back through the IL-1 receptor → myd88/IRAK/TRAF6 → tak1 → IKK → NF-κB → more IL-1α and more inflammatory SASP factors. This creates a positive-feedback circuit that maintains NF-κB in the “on” state indefinitely ³. Blocking IL-1R signaling with IL-1Ra (anakinra) or IL-1α antibodies partially reduces SASP output in senescent fibroblasts.
• DNA damage response (DDR) input — the DNA damage response, chronically active in senescent cells due to persistent double-strand breaks and telomeric dysfunction, feeds NF-κB through ATM → NEMO (IKKγ) SUMOylation/ubiquitination → IKK → nuclear NF-κB; and through the cGAS-STING axis (cytosolic chromatin fragments → cGAMP → STING → IKK → NF-κB).
• mTORC1 cooperation — mTORC1 amplifies SASP protein output post-transcriptionally via 4E-BP1 and the MK2/HuR mRNA stabilization axis, acting downstream of the NF-κB transcriptional signal. Rapamycin suppresses SASP without eliminating NF-κB activation per se, making this a translational (not transcriptional) contribution. See sasp for detail; primary citations needed. unsourced

The canonical SASP cytokines — IL-6, IL-8 (CXCL8), IL-1α, IL-1β, CXCL1, CCL2 — all carry κB sites in their promoters and are direct NF-κB targets. Coppé et al. 2008 systematically characterized the secretory profile of senescent human fibroblasts across five cell strains; the SASP required 4–7 days after senescence induction to develop robustly (cells irradiated at 10 Gy developed a SASP, while 0.5 Gy produced only transient arrest) ⁴. NF-κB pathway inhibition suppression of SASP output is established in the Freund 2010 review ³; Coppé 2008 itself characterized the secretory profile but did not include NF-κB inhibition experiments.

Inflammaging — systemic chronic low-grade NF-κB activity

Beyond senescent-cell SASP, NF-κB is aberrantly activated in aged tissues more generally — in post-mitotic cells that are not senescent and in non-immune cell types ⁵. This broad activation contributes to the chronic low-grade sterile inflammation of aging (“inflammaging”):

• Age-accumulated ROS directly activate IKKβ and oxidize IκBα (impairing re-synthesis), shifting the NF-κB activation/repression balance toward chronic activation.
• Mitochondrial dysfunction with age leads to release of DAMPs (mtDNA, cardiolipin, TFAM) that activate TLR9, cGAS-STING, and NLRP3 inflammasome → NF-κB.
• Gut microbiome shifts with age (“dysbiosis”) increase circulating LPS → systemic TLR4/NF-κB activation. unsourced (specific mechanistic studies needed; magnitude of microbiome contribution to systemic NF-κB in humans not established)

The NF-κB transcriptional program accelerates with age in multiple human tissues. Genomewide chromatin immunoprecipitation studies in aged mouse tissues (brain, liver) show increased NF-κB occupancy at inflammatory gene promoters compared to young animals. needs-human-replication (human tissue ChIP-seq data on NF-κB with age is sparse)

Dimension	Status
Pathway conserved in humans?	yes
Inflammaging phenotype conserved in humans?	yes — elevated CRP, IL-6, TNF-α with age are well-documented in humans
Mechanistic link (NF-κB → SASP) confirmed in humans?	partial — human fibroblast data (Coppé 2008); in-vivo human interventional data limited

NF-κB target genes relevant to aging

NF-κB binds hundreds of target loci; the aging-relevant subset clusters around inflammation, cell survival, and senescence:

Category	Key targets	Aging relevance
Pro-inflammatory cytokines	IL6, IL8, IL1A, IL1B, TNF	Core SASP factors; systemic inflammaging drivers
Chemokines	CXCL1, CXCL2, CCL2, CXCL10	Immune cell recruitment; paracrine senescence
Anti-apoptotic	BCL2, BCL-XL, cIAP1/2, SURVIVIN	Senescent cell survival (contributes to senescent cell accumulation)
Cell cycle regulators	CDKN1A (p21)	Can reinforce senescence arrest in a context-dependent manner
ECM remodelers	MMP1, MMP3, MMP9, uPA	Tissue remodeling; tumor microenvironment
Innate immune mediators	NLRP3, TLR2, complement	Inflammasome priming; innate immune escalation

Pharmacological targeting

NF-κB inhibition strategies in aging contexts

Complete, systemic NF-κB inhibition is immunosuppressive and carries unacceptable risks (increased susceptibility to infection and cancer). Aging-relevant interventions aim for partial, context-selective, or cell-type-specific NF-κB attenuation ²:

Strategy	Example compounds	Mechanism	Notes
IKK inhibitors	Parthenolide, BMS-345541, TPCA-1	Directly inhibit IKKβ kinase	Broad anti-inflammatory; immunosuppression risk limits clinical use
IκBα “super-repressor” transgene	Genetic approach	Non-degradable IκBα blocks p65/p50 nuclear translocation	Mouse longevity data (see below); not clinically translatable as stated
Salicylates	Aspirin (high dose), sodium salicylate	Inhibit IKKβ at high doses; also COX-1/2 at lower doses	Mechanism at anti-inflammatory doses is largely COX-dependent; IKK inhibition requires ~mM concentrations dose-response-unclear
BET bromodomain inhibitors	JQ1, I-BET762	BRD4 cooperates with p65 on SASP-associated super-enhancers; BRD4 inhibition suppresses SASP gene expression	Preclinical anti-senescence/SASP data; clinical trials for oncology; aging use preclinical needs-human-replication
JAK1/2 inhibitors	Ruxolitinib, baricitinib	Block IL-6 / IFN signaling downstream of SASP; also reduce upstream NF-κB-activating cytokine feedback	Clinical trials in aging (Myriad RejuvenaBio); reduces some SASP markers in pilot studies
Anti-IL-1β (canakinumab)	CANTOS trial (Phase 3)	Neutralizes IL-1β → interrupts NF-κB autocrine amplification loop	Reduced cardiovascular events (150 mg: HR 0.85) 6; exploratory cancer mortality reduction (300 mg: HR 0.49) reported in separate Lancet paper 7; designed for atherosclerosis, not aging
Senolytic / senomorphic combos	Fisetin + BRD4i	Clear senescent cells (senolytic) or suppress SASP (senomorphic)	Indirect NF-κB targeting via reducing senescent cell burden

CANTOS trial context

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) Phase 3 RCT (n=10,061; median follow-up 3.7 years) tested subcutaneous canakinumab (anti-IL-1β monoclonal antibody) 50, 150, or 300 mg q3mo vs. placebo in patients with prior MI and elevated hsCRP (≥2 mg/L) ⁶. Results relevant to the aging-inflammation axis:

• Primary endpoint (non-fatal MI, non-fatal stroke, cardiovascular death): only the 150 mg dose met the prespecified multiplicity-adjusted significance threshold, reducing the primary endpoint hazard ratio to 0.85 (95% CI 0.74–0.98; p=0.021). The 300 mg dose showed HR 0.86 (95% CI 0.75–0.99; p=0.031) but the threshold for that arm was p<0.01058, so it did not formally meet significance ⁶. needs-replication — single large trial; no independent replication RCT exists.
• Cancer mortality (exploratory, from a separate Lancet analysis of the same trial data): total cancer mortality was significantly lower in the pooled canakinumab group (p=0.0007 for trend); the HR 0.49 (95% CI 0.31–0.75; p=0.0009) specifically applies to the 300 mg group, not 150 mg ⁷. Incident lung cancer was reduced at 150 mg (HR 0.61, 95% CI 0.39–0.97) and 300 mg (HR 0.33, 95% CI 0.18–0.59). These are hypothesis-generating exploratory results requiring replication in formal cancer-prevention settings.
• hsCRP fell 37 percentage points greater than placebo at the 150 mg dose at 48 months ⁶. IL-6 showed “similar effects” per the primary paper; the separate Lancet analysis reported dose-dependent IL-6 reductions of 25–43% across all dose groups ⁷. needs-replication
• CANTOS does not directly test NF-κB inhibition, but canakinumab operates on the IL-1β limb of the NF-κB autocrine loop; the results provide human proof-of-concept that interrupting chronic NF-κB-axis inflammation reduces cardiovascular events.

The trial was designed for atherosclerosis, not aging per se; extrapolation to healthy aging populations requires caution. needs-human-replication

NF-κB and lifespan in model organisms

Partial NF-κB inhibition has been tested in several organisms with longevity-relevant outcomes. The picture is nuanced — complete inhibition is harmful; partial inhibition in specific contexts can extend healthspan and/or lifespan.

Organism	Intervention	Outcome	Reference
Mus musculus	NF-κB essential modifier (NEMO) heterozygous knockout — partial IKK reduction in skin	Delayed aging phenotype in skin; reduced age-associated inflammation	unsourced — specific NEMO het mouse longevity claim needs primary citation
Mus musculus	Epidermis-specific IκBα super-repressor transgene	Premature aging phenotype — NF-κB is required for normal tissue homeostasis; complete epithelial inhibition is harmful	unsourced
Drosophila	Partial reduction of Relish (NF-κB ortholog)	Extended lifespan ~6–15% in Relish-reduced flies	unsourced — single-study; needs primary citation
C. elegans	nfkb-1 / rel-1 partial reduction	Mixed; context-dependent on immune challenge status	unsourced

Key caveat for all model-organism NF-κB lifespan data: The benefit appears narrowly dose-dependent — partial reduction in specific tissues (especially immune and adipose) shows benefit, but systemic or complete inhibition accelerates pathology. This non-linearity is poorly modeled in any single transgenic system. None of these observations has been replicated in humans. needs-human-replication

Connection to other aging pathways

• sasp — NF-κB is the master transcriptional driver of SASP; the IL-1α autocrine loop links SASP maintenance to NF-κB persistence in senescent cells ^{3 4}.
• dna-damage-response — DDR → ATM/ATR → NF-κB (nuclear IKK activation via SUMOylated NEMO) is a major activating route; persistent DDR in aged cells feeds NF-κB constitutively.
• cgas-sting — cytosolic chromatin sensing in senescent cells activates STING → IKK → NF-κB; parallel and synergistic with direct DDR input.
• mtor — mTORC1 cooperates with NF-κB post-transcriptionally to amplify SASP output; rapamycin reduces SASP protein levels without fully abolishing NF-κB-driven transcription. The mTOR-NF-κB relationship is not purely upstream/downstream — there is evidence for bi-directional cross-talk at the level of AKT → IKK. See mtor.
• atm — ATM directly phosphorylates and activates IKKγ/NEMO in the nucleus following double-strand break recognition, linking genotoxic stress to inflammatory gene activation.
• p53-pathway — p53 and NF-κB have a complex, context-dependent antagonism; p65 can inhibit p53-dependent transcription and vice versa. In senescent cells, both are simultaneously active, but their targets are partly non-overlapping.
• insulin-igf1 — insulin/IGF-1 → PI3K → AKT activates IKKβ, providing a metabolic input to NF-κB; conversely, chronic NF-κB in adipose tissue promotes insulin resistance via IKKβ-mediated IRS-1 serine phosphorylation (serine phosphorylation prevents tyrosine activation of IRS-1).
• ampk — AMPK inhibits NF-κB at multiple levels: directly via IKKβ phosphorylation (inhibitory), indirectly via reducing mTORC1-mediated amplification of SASP output. AMPK activators (metformin, exercise) reduce some NF-κB-target inflammatory markers. unsourced (specific NF-κB inhibitory sites for AMPK need primary citations)
• chronic-inflammation — this hallmark is largely operationalized as systemic NF-κB activity in aging tissues; NF-κB is its primary mechanistic driver.
• immunosenescence — age-associated remodeling of the immune system (reduced adaptive, dysregulated innate) involves NF-κB dysregulation in both lymphocytes and myeloid cells; the SASP-driven cytokine milieu further drives immunosenescence.

Limitations and gaps

• Complete NF-κB inhibition is harmful. NF-κB is required for normal immune responses, tissue repair, and apoptosis. Therapeutic strategies must be partial, intermittent, or cell-type-targeted to avoid immunosuppression. The therapeutic window has not been established in humans for any aging indication. dose-response-unclear
• Cell-type specificity is poorly mapped in vivo. NF-κB’s aging effects have been characterized mainly in fibroblasts, epithelial cells, and macrophages; adipose and neuronal NF-κB contributions to systemic inflammaging are under-studied. needs-replication
• Human NF-κB tissue-level activation data with age is sparse. Most evidence for increased NF-κB activity with aging comes from mouse or cell-culture models. Human tissue ChIP-seq or transcriptomics showing NF-κB occupancy increases with age is limited. needs-human-replication
• CANTOS is the only large human trial interrogating the NF-κB axis in an aging-relevant way, and it was designed for atherosclerosis, not aging per se; the secondary cancer finding needs replication. needs-replication
• The non-canonical NF-κB arm’s role in inflammaging is understudied. Most inflammaging research focuses on canonical p65/p50; the p52/RelB arm and its age-related dynamics are not well-characterized. needs-replication
• BET bromodomain inhibitor data in aging is preclinical only. BRD4 cooperates with p65 on SASP super-enhancers; JQ1 reduces SASP in vitro, but clinical translation to aging has not advanced beyond early-phase oncology trials. needs-human-replication

Footnotes

Footnotes

1. doi:10.1016/j.cell.2008.01.020 · review · Hayden MS & Ghosh S · Cell 2008 · n/a (review) · cited 4,635× · covers IKK complex, both activation arms, feedback regulation, transcriptional mechanisms, and disease context · archive status: locally downloaded ↩ ↩² ↩³ ↩⁴

2. doi:10.1101/gad.183434.111 · review · Hayden MS & Ghosh S · Genes & Development 2012 · n/a (review) · cited 1,636× · covers first 25 years of NF-κB research including therapeutic targeting and outstanding mechanistic questions · κB consensus 5′-GGGRNWYYCC-3′ (N=any, R=purine, W=A or T, Y=pyrimidine) · archive status: locally downloaded (diamond OA) ↩ ↩² ↩³ ↩⁴

3. doi:10.1016/j.molmed.2010.03.003 · review · Freund A et al. (Campisi lab) · Trends in Molecular Medicine 2010 · n/a (review) · cited 1,308× · covers IL-1α autocrine loop maintaining NF-κB in senescent cells; SASP develops over several days; immune clearance of senescent cells · archive status: download failed; PMC full-text accessible (PMC2879478) · no-fulltext-access (local PDF unavailable) ↩ ↩² ↩³ ↩⁴

4. doi:10.1371/journal.pbio.0060301 · in-vitro + in-vivo · Coppé JP et al. (Campisi lab) · PLoS Biology 2008 · n=5 human fibroblast strains + prostate epithelial cells · foundational characterization of SASP secretory profile; SASP requires 4–7 days post-senescence induction to develop robustly (10 Gy irradiation required; 0.5 Gy produced only transient arrest); does not include NF-κB inhibition experiments — NF-κB inhibition data belongs to Freund 2010 · model: human diploid fibroblasts and epithelial cells · archive status: locally downloaded ↩ ↩²

5. doi:10.1016/j.arr.2007.09.002 · review · Salminen A et al. · Ageing Research Reviews 2008 · n/a (review) · cited 562× · NF-κB as molecular culprit of inflamm-aging; age-related innate immune activation · archive status: not_oa · no-fulltext-access ↩

6. doi:10.1056/NEJMoa1707914 · rct · Ridker PM et al. (CANTOS Investigators) · New England Journal of Medicine 2017 · n=10,061 · Phase 3 RCT, median follow-up 3.7 years · canakinumab (anti-IL-1β) 150 mg q3mo reduced primary MACE endpoint HR 0.85 (95% CI 0.74–0.98; p=0.021); all-cause mortality HR 0.94 (95% CI 0.83–1.06; p=0.31, ns) · cancer mortality reported as exploratory only in primary paper; full cancer analysis in separate Lancet publication · model: human (prior MI, elevated hsCRP ≥2 mg/L) · archive status: locally downloaded ↩ ↩² ↩³ ↩⁴

7. doi:10.1016/S0140-6736(17)32247-X · rct (exploratory cancer analysis of CANTOS) · Ridker PM et al. · Lancet 2017 · n=10,061 · cancer mortality HR 0.49 (95% CI 0.31–0.75; p=0.0009) for 300 mg group only; pooled group p=0.0007 for trend · incident lung cancer HR 0.61 (150 mg) and 0.33 (300 mg) · IL-6 reduced 25–43% across dose groups · hypothesis-generating; replication required · archive status: not checked ↩ ↩² ↩³